Clinical Trials
72 trialsNCT01298323 2026-04-17
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
Phase 3 Completed
NCT01582191 2025-10-27
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01496313 2025-10-03
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Sanofi
Phase 4 Completed
NCT00410761 2025-09-24
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
Phase 3 Completed
NCT01601808 2025-03-13
ViP
University of Liverpool
Phase 2 Completed
NCT00418886 2024-12-31
ZEAL
Sanofi
Phase 3 Completed
NCT01876784 2024-07-23
VERIFY
Sanofi
Phase 3 Completed
NCT00537095 2024-04-19
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
Sanofi
Phase 2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT01586624 2021-10-07
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
Phase 1 Completed
NCT01183559 2021-01-22
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Fox Chase Cancer Center
Phase 1 Completed
NCT01414426 2021-01-14
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
University of Chicago
Phase 2 Completed
NCT00514046 2020-12-22
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01823068 2020-12-07
Vandetanib in Advanced NSCLC With RET Rearrangement
Samsung Medical Center
Phase 2 Completed
NCT02015065 2020-03-30
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00613626 2020-02-11
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00272350 2019-12-05
ZD6474 to Treat Advanced Brain Cancer in Patients
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01191892 2019-05-16
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00441142 2019-03-05
Zactima
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00566995 2018-10-30
Phase II Study of Vandetanib in Individuals With Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00880334 2018-09-18
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00687297 2018-05-30
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
PrECOG, LLC.
Phase 2 Completed
NCT00098345 2018-05-07
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Sanofi
Phase 2 Completed
NCT00364351 2018-01-25
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Sanofi
Phase 3 Completed
NCT00500292 2018-01-25
A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Sanofi
Phase 2 Completed
NCT01539655 2017-05-02
Vandetanib
Sanofi
Phase 1 Completed
NCT00358956 2017-01-30
A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Sanofi
Phase 2 Completed
NCT00872989 2016-12-19
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00659438 2016-12-05
Efficacy and Safety of Zactimaâ„¢ in Patients With Castration-refractory Metastatic Prostate Cancer
Sanofi
Phase 2 Completed
NCT01661179 2016-12-05
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Sanofi
Phase 1/2 Completed
NCT00753714 2016-10-17
ZELIG
Sanofi
Phase 2 Completed
NCT00508001 2016-10-10
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
Sanofi
Phase 2 Completed
NCT00753675 2016-10-10
VANGOGH
Sanofi
Phase 2 Completed
NCT00777179 2016-10-10
Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
Sanofi
Phase 2 Completed
NCT00454116 2016-10-07
A Phase II, Double Blind Study of 2 Doses of ZACTIMAâ„¢(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Sanofi
Phase 2 Completed
NCT00498797 2016-10-07
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00312377 2016-09-30
ZODIAC
Sanofi
Phase 3 Completed
NCT00404924 2016-09-30
ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures
Sanofi
Phase 3 Completed
NCT00494481 2016-09-30
E3 Breast Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00503711 2016-08-31
Phase I Chinese PK
Sanofi
Phase 1 Completed
NCT00450138 2016-08-29
Open Label, Phase I ZD6474 Head and Neck Cancer Study
Sanofi
Phase 1 Completed
NCT00681798 2016-08-29
Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma
Sanofi
Phase 1 Completed
NCT00496275 2016-08-26
Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC
Sanofi
Phase 1 Completed
NCT00496509 2016-08-26
Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer
Sanofi
Phase 1 Completed
NCT00047840 2016-08-25
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
Sanofi
Phase 2 Completed
NCT00071188 2016-08-25
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00252746 2016-08-25
ZD6474 Phase IIa Dose Finding Multicentre Study
Sanofi
Phase 2 Completed
NCT00499850 2016-08-25
Phase I FOLFOX Combination
Sanofi
Phase 1 Completed
NCT00506051 2016-08-25
ZD6474(Vandetanib) + Alimta Combo Study
Sanofi
Phase 1 Completed